US 12,029,766 B2
Pharmaceutical composition and methods for the prevention and/or treatment of Staphylococcus aureus using artificial bacterial colonization
Jean-Louis Gaillard, Issy les Moulineaux (FR); Didier Guillemot, Paris (FR); Jean-Louis Herrmann, Bourg la Reine (FR); Martin Rottman, La Celle Saint-Cloud (FR); Anne-Sophie Alvarez, Bievres (FR); Jérôme Salomon, Paris (FR); and Valérie Lesellier, Igny (FR)
Assigned to UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, Versailles (FR); and ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR)
Filed by UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, Versailles (FR); and ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR)
Filed on Feb. 7, 2019, as Appl. No. 16/270,296.
Application 16/270,296 is a continuation in part of application No. PCT/EP2018/071528, filed on Aug. 8, 2018.
Claims priority of application No. 17306056 (EP), filed on Aug. 8, 2017.
Prior Publication US 2019/0167734 A1, Jun. 6, 2019
Int. Cl. A61K 35/74 (2015.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 35/00 (2006.01); A61K 35/66 (2015.01); A61P 31/04 (2006.01); C12N 1/20 (2006.01)
CPC A61K 35/74 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0043 (2013.01); A61K 9/19 (2013.01); A61K 35/00 (2013.01); A61K 35/66 (2013.01); A61P 31/04 (2018.01); C12N 1/20 (2013.01)] 19 Claims
 
1. A method for treating colonization by Staphylococcus aureus in a subject in need thereof, the method comprising administering a pharmaceutical composition comprising (A) at least one Corynebacterium propinquum AF1882 (CNCM I-5393) or Corynebacterium accolens, (B) Staphylococcus pasteuri, and (C) a pharmaceutically acceptable excipient,
wherein said pharmaceutical composition reduces the colonization of Staphylococcus aureus in the subject.